GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Valuation Rank

Ourofino (BSP:OFSA3) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Ourofino Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ourofino Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ourofino's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ourofino Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Valuation Rank
Comparable Companies
BSP:BLAU3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Website
https://www.ourofinosaudeanimal.com
Ouro Fino Saude Animal Participacoes SA is engaged in the production and sale of veterinary drugs, vaccines, and other products for cattle, pigs, poultry, sheep, horses goats, and pets. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.